Tesamorelin

Name: Tesamorelin
Availability: InStock

2mg vial

Tesamorelin is a stabilised 44-amino-acid GHRH analogue, FDA-approved as Egrifta for HIV-associated lipodystrophy. It produces a robust GHRH-driven GH/IGF-1 pulse and is the most clinically validated GHRH analogue for visceral adipose tissue (VAT) reduction without compromising subcutaneous fat or lean mass.

Select size

Checking availability…

Researched for

approx. 18% mean visceral adipose tissue reduction in Phase 3 (LIPO trials)
Improved IGF-1 levels and lipid profile in clinical research
Selective VAT loss without subcutaneous fat or lean mass loss
Preserved insulin sensitivity vs exogenous HGH protocols
Improved sleep architecture and recovery via natural GH pulse
Synergistic when stacked with Ipamorelin or other GHRPs

Mechanism of action

Binds pituitary GHRH receptors to stimulate endogenous GH synthesis and release, with downstream IGF-1 elevation. N-terminal modification protects against DPP-4 degradation, extending half-life vs native GHRH.

Research protocol

Standard research/clinical protocols use 1–2mg subcutaneously once daily, typically pre-sleep. Cycles typically run 12–26 weeks with reassessment. Often stacked with a GHRP (e.g. Ipamorelin) for amplified pulse synergy.

Half-life

approx. 25–40 minutes plasma; functional GH/IGF-1 elevation persists 12–24 hours.

Reconstitution

Reconstitute a 5mg vial with 1–2mL bacteriostatic water for a 2.5–5mg/mL working concentration. Swirl gently - do not shake.

Storage

Lyophilised: 2–8°C, stable 24 months. Reconstituted: 2–8°C, use within 14–28 days depending on diluent.

Research considerations

• Injection-site reactions (redness, itching, swelling) are common.
• Joint pain, peripheral oedema and paraesthesia reported in clinical trials.
• Glucose tolerance should be monitored - modest insulin resistance can occur at higher doses.